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Until recently, the clinical significance of post-surgical pain and its undertreatment were for
the most part unappreciated. Recognition that inadequate analgesia adversely affects the
patient's cardiovascular, pulmonary, and emotional status has spurred development of new and
highly effective methods of controlling pain. With the introduction of spinal opioid and
patient-controlled analgesia (PCA) came the realization that, while such forms of therapy
provided superior pain relief, they were not without their own unique and occasionally serious
side effects. For this reason, both techniques are more safely provided by highly trained
members of a dedicated acute/post-surgical pain service.
Although spinal opioid (epidural, intrathecal) techniques are invasive and require patient
cooperation, they have a high degree ofsafety in low-risk populations (ASA 1 and 2). The major
therapeutic advantage ofspinal opioids is their ability to prevent pain from being perceived.
PCA permits patients to titrate intravenous opioids in proportion to their particular level of
pain intensity. Although PCA provides effective pain "relief," the technique is incapable of
preventing pain from being appreciated. A number ofstudies have observed that pain scores in
patients successfully employing PCA were significantly higher than those noted in individuals
treated with epidural opioids. Nevertheless, the control gained by self-administration, unifor-
mity of analgesia, and low level of adverse results associated with PCA provides higher patient
satisfaction and decreased sedation when compared with traditional intramuscular dosing. The
effectiveness of PCA may be improved by adjusting for patient variables, utilizing opioids
having rapid onset, the addition of a basal infusion, and supplementation with non-steroidal
anti-inflammatory agents.
Interpleural analgesia represents an important therapeutic option in patients sensitive to
opioid-induced respiratory depression. The technique is more effective when local anesthetic
solutions are continually infused. Analgesic efficacy may be further enhanced by the addition of
"low-dose" PCA.
INTRODUCTION
Although pain is among the most common of symptoms encountered by the
hospital staff, it remains one of the most poorly treated. In a well-documented
post-operative study, 32 percent of patients reported severe pain and 41 percent
experienced moderate pain in the post-surgical period [1]. It is now apparent that
with traditional as-required (PRN) dosing, a number ofvariables, including patient
age, ASA status, site and extent ofinjury, and coping skills, must be accounted for in
the algorithm ofproviding adequate analgesia. Most patients are either intentionally
(fear of adverse drug effect, respiratory depression, addiction, and the like) or
unintentionally (poor understanding of onset, minimal effective plasma concentra-
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tion, half-life ofanalgesic effect) undermedicated [2]. Many are prescribed analgesic
dosages that are less than half of what is required to relieve pain adequately. In
addition, nurses may further reduce dosage, leading to the patient's accurate
perception that analgesics were not administered in a high enough dose or as
frequently as was required [2,3]. Some workers have shown that the amount of pain
medication apatient receives isdirectly related to the numberofnurses on duty [1,2].
During the last decade, the medical community has become increasingly con-
cerned over the significant morbidity associated with poorly controlled post-surgical
pain. The importance ofreducing emotional, hormonal, and neural stress responses
associated with moderate to severe discomfort has emphasized the need for clinical
specialists trained to formulate strategies that provide more uniform and effective
levels of analgesia. The anesthesiologist, having a thorough understanding ofopioid
pharmacology, and skilled in regional forms of drug administration, is uniquely
qualified for this role. Workers in this specialty have long recognized that there are
more similarities than differences between numerous opioid derivatives, and that
what was necessary for more effective pain management was the development of
more appropriate methods of drug delivery [3]. In this regard, departments of
anesthesiology have made significant contributions toward the clinical utilization of
three new methods of pain control: namely, the "selective" analgesia provided by
spinally acting opioids, the "demand" analgesia offered bypatient-controlled admin-
istration of intravenous opioids, and interpleural catheter techniques utilizing local
anesthetics.
In an effort to improve the availability and appropriate follow-up of patients
treated with these new techniques, Ready and co-workers [4] have inspired develop-
ment ofphysician (usually anesthesiology-based) "Acute Pain Services." Acute pain
services offer in-house individuals trained to provide both nursing and patient
education, individualized epidural opioid and PCA dose, assess the effectiveness of
and adjust ongoing therapy, and treat associated side effects. New methods of
providing post-operative analgesia via organized pain services are becoming increas-
inglywidespread and have been found to be more effective and safer than traditional
forms ofopioid delivery.
TRADITIONAL METHODS OF PAIN CONTROL
Intramuscular administration of opioid analgesics, repeated every three to four
hours, remains the most widely used method of pain control. While most physicians
are comfortablewith the ease andsimplicityofPRNorby-the-clockdosing, the onset
ofanalgesia is often delayed, and clinical effectivenessmaybeunpredictable. When a
parenteral analgesic is administered [either intramuscularly (IM) or subcutaneously
(SC)] every three to four hours, concentrations in plasma may equal or exceed
minimal analgesic concentration during only 35 percent of the dosing interval [3].
Moreover, peak plasma concentrationsvarybetween three- and fivefold, and time to
reachpeakactivity, seven- to fifteenfold amongindividuals [5]. Thus, it is understand-
able why attempts at predicting the amount of opioid needed for an individual
patient have met with little success. Many authors [3,4,6] have shown that older
patients require less opioid; however, whether this finding is related to alterations in
pharmacokinetics (smallervolume ofdistribution) orpharmacodynamics (changes in
central nervous system access, opiate receptor density, binding affinity, and so on)
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remains unclear. Other investigators have shown that obese individuals require more
post-operative analgesics, yet attempts at demonstrating relationships among height,
weight, and body surface area have provided little success [6]. The reason for failure
may be in part due to the manner in which the drugs are administered but is also
related to large inter-individual variation regarding perceived intensity ofthe painful
stimulus over time [3].
Asnoted in Fig. 1, the traditional PRN every three-to-four-hour dosinginvolves an
elaborate sequence of events which inevitably delays administration by at least 30
minutes to an hour. In addition, one typically notices the repetitive cycle ofincreases
in pain followed by excessive sedation-narcosis after absorption ofthe opioid.
When a patient initiates a request for medication, a variable delay occurs before
the nurse arrives. Because pain may not be considered an emergency, the length of
time patients wait is dependent upon the situation on the ward (and nursing
workload) at the time of the request. Once the nurse has responded, he or she
usually initiates a "screening" of the complaint to assess whether the patient really
needs additional pain medication. Despite published research indicating that physi-
cal dependence occurs in fewer than 0.1 percent of hospitalized patients, this
screening is done presumably in order to avoid opioid abuse [2,3,7].
When the level of pain is deemed appropriate and requiring treatment, a long
sequence of events occurs before the patient actually achieves relief. The nurse must
sign out the medication, prepare an injection, and administer the dose. The drug
must then be absorbed from the IM or SC site of administration, achieve effective
plasma concentration, and interact at central nervous system (CNS) receptor sites.
Since the dose administered is relatively large and absorption is erratic and pro-
longed, the initial analgesic effect is often followed by sedation and some degree of
respiratory depression. In point of fact, the presence of sedation is often equated
with a satisfactory analgesic effect [1,2].
Other traditional delivery options include PRN boluses of intravenous opioids in
which the advantage ofrapid onset must be coupled with shorter analgesic duration
and increased labor intensity. Timed-release oral morphine and "depot" methadone
offer advantages ofprolonged duration (but because dosage is high, possibly greater
side effects) and deserve further study.
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CLINICAL USE OF SPINAL OPIOIDS'
Pharnacology
The identification of specific opioid binding sites, receptor subtypes, and the
discovery of the endogenous opioid peptides has helped to clarify how and where
these useful agents interact with the nervous system; nevertheless, considerable
controversy has existed regarding the effects of opioids at the spinal level. Earlier
investigators favored the view that systemically administered opioids had major
impact on supraspinal centers or activated descending pathways, which inhibited
transmission ofnociceptive information at the spinal level, rather than having direct
effects at the cord [3,5]. Follow-up studies presented evidence of significant opioid
suppression of spinal nociceptive neurons. Kitahata and Collins [8] had reasoned
that small amounts of opiate receptor binding in a strategic location (dorsal horn)
could have major effect on pain modulation since nociceptive input could be
effectively blunted at the first synapse in the CNS. These investigators were first to
demonstrate a dorsal horn suppressive effect of morphine upon nociceptive cells in
laminae I and V. This effect was quite selective, since the activity of neurons of
laminae IV and VI, which respond to non-noxious cutaneous and proprioceptive
stimuli, was unaffected. Similar opioid suppressive effects reported by Duggan et al.
[9] were related to specific receptor binding,which could be reversedbyiontophoret-
ically administered naloxone.
Autoradiographic techniques, in which radiolabeled opioids are employed to
localize sites of activity, have demonstrated a remarkable correlation between the
above-mentioned neurophysiology and those regions havinghighestbinding. Autora-
diographs prepared by Pert et al. [10] revealed that specific opioid binding in spinal
cord was restricted to the dorsal horn. In a more detailed study, dorsal horn binding
densitywas found to be highest in laminae I and II. Autoradiographs made following
spinal application of radiolabeled morphine show that, as the front of radioactivity
penetrating dorsal horn reaches laminae II and V, the discharge of neurons to
noxious stimuli begins to decrease [11].
Attempts have been made to carry the localization of opiate receptors one step
further and determinewhetherthey are located pre- orpost-synaptically with respect
to the primary afferent fibers in the spinal cord. Evidence exists forboth a pre- and a
post-synaptic location. A study by LaMotte et al. [12] showed a significant reduction
in stereospecific opiate binding in the dorsal horn of monkeys following rhizotomy,
suggesting a pre-synaptic receptor location. In cats, morphine depressed nociceptive
responses when injected into the substantia gelatinosa but not at more ventral sites
where cell bodies are located. Enkephalin depresses cell firing at either location,
suggesting that receptors for morphine may be restricted to pre-synaptic terminals,
while enkephalin may also act upon post-synaptic dendrites [13].
Behavioral Studies
While the above studies demonstrated clear evidence of opioid receptor binding
and activity at the spinal level, it was not clear whether spinal opioids would provide
useful analgesia in the intact organism. This question was answered by administering
small amounts of opiates through chronically implanted catheters into the spinal
'Unless specifically described, the term "spinal opioids" is used to identify the site of action and
analgesic effect provided by intrathecal or epidurally administered agents.
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TABLE 1
Opiate Receptor Subtypesa
Tail Flick Hot Plate Writhing
Mu Agonists Powerful Powerful Suppression
suppression suppression
Kappa Agonists Weak Weak Powerful
suppression suppression suppression
Delta Agonists Suppression Suppression No suppression
Mu/Delta Synergistic Synergistic Weak suppression
Agonists suppression suppression
aSummarized from [16,17]
space of intact animals [14-16]. Utilizing this model, Yaksh and Rudy [14] showed
that small doses (40-160 ,ug) ofintrathecal morphine produced behaviorally defined
naloxone-reversible analgesia of prolonged duration. These investigators have pro-
vided evidence that two or more distinct opioid receptor systems may be involved in
modulating pain at the spinal level [15,16]. Intrathecally administered nalbuphine, a
kappa receptor agonist, had no antinociceptive effect in rats exposed to thermally
evoked stimuli (tail flick, hot plate), but had a powerful suppressive effect against
visceral-chemical stimuli (acetic acid writhing test). Morphine, a mu-kappa agonist,
was found to be effective against both cutaneous-thermal and visceral/chemical
stimuli [16]. In a follow-up study, Schmauss and Yaksh [17] were able to characterize
further spinal opioid binding by showing that delta receptor agonists (metkephamid,
DADL) attenuated thermally evoked responses but were less effective in blunting
visceral stimulation. Table 1 outlines present understanding of opioid receptor
subtypes in spinal cord.
From the above discussion, the following picture begins to emerge. Noxious
stimuli relayed to the dorsal horn by unmyelinated nociceptive afferents (C fibers)
result in the release of substance P at synapses with second-order neurons [substan-
tiagelatinosa (SG) cells]. The SG cells in turn drive neurons oflaminae VII and VIII
whose axons ascend as the spinoreticular-spinothalamic tract and synapse in the
periaqueductal grey and medial thalamus. Such input is modulated by two distinct
mechanisms. The first is mediated bylocal release ofendogenous opioids from spinal
interneurons that bind mu, kappa, and delta receptors at pre- and post-synaptic sites
[15-17]. Receptor activation inhibits further transmission ofnociceptive impulses by
blocking substance P release or by stabilizing second-order SG cells. The second
mechanism is mediated by descending inhibition from the brain stem reticular
formation, periaqueductal grey, and nucleusraphemagnus [14,17,18]. These descend-
ing adrenergic, enkephalinergic, and serotoninergic axons either inhibit pre- and
post-synaptic membranes directly or facilitate release of endogenous spinal opioids.
Both mechanisms have close association with the paleospinothalamic tract [9,12],
which is responsible for transmission ofslow-dull pain, and have little relationship to
the neospinothalamic tract, responsible for mediating sharp pain.
In the clinical setting, intravenous opiates activate both mechanisms in dose-
dependent fashion, while intrathecally administered opioids maximally activate
spinal receptor sites and have less impact on descending pathways. Figure 2
illustrates mechanisms whereby nociceptive input is modulated in the dorsal horn.
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FIG. 2. Pain modulation in the dorsal horn. Local modulation includes enkephalin-
ergic inhibition of substance P release. Descending modulation includes enkeph-
alinergic, noradrenergic, and serotonergic fibers, which either activate local
enkephalinergic inter-neurons, inhibit substance P release, or decrease the excitabil-
ity ofsecond-order (SG) cells.
PhysiochemicalProperties
The complex pharmacokinetics that follow opioid deposition into the epidural
space have been outlined [18] and must be appreciated in order to understand the
benefits and potential complications of spinal analgesia. Although many factors
including dose, volume of injectate, molecular weight, and shape are considered
importantvariables, lipid solubility appears to play thekeyrole in determining onset,
dermatomal spread, and duration ofanalgesia [18]. In this regard, delayed analgesic
onset noted with morphine has been related to its low lipid solubility, which reduces
dural permeability and, more important, retards penetration into spinal tissue [19].
Following administration, significant amounts of drug become sequestered in cere-
brospinal fluid (CSF) for relatively long periods of time. This aqueous "depot" of
unbound morphine molecules may provide analgesia of prolonged duration, but is
the major causative factor underlying delayed respiratory depression [18,19].
Spinal administration of opioids produces dose-dependent analgesia of greater
potency than similar doses administered parenterally. This potency gain is inversely
related to lipid solubility as the blood-brain barrier is bypassed [18]. A second major
advantage noted with spinally administered opioids is the "selectivity" of analgesic
effect, which occurs in the absence of motor or sympathetic blockade, potentially
allowing patient ambulation and the avoidance ofcardiovascular collapse.
Initial Clinical Studies
The efficacy of spinal opioids in animal studies, coupled with established tech-
niques for administering drugs into the spinal and epidural spaces, provided a new
and potentially useful method of controlling pain in a variety of clinical settings.
Although intrathecal morphine may have been used clinically over 80 years ago,
Wang and colleagues in 1979 were the first to report a double-blind, controlled study
ofspinally administered opioids in humans [20]. In six out ofeight patients suffering
from intractable cancer pain, intrathecal morphine (0.5-1.0 mg) produced complete
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TABLE 2
Analgesic Efficacy and Frequency ofAdverse Effects with Epidural, PCA, and IM Morphine
No. of Patients with % of Patients
Good Post-Operative % ofPatients with Urinary
Analgesia with Pruritus Retention
Study No. Epidural PCA IM Epidural PCA IM Epidural PCA
I 65 40 25 85 60 35 NA NA
II 85 60 50 72 38 17 NA NA
III 95 50 NA 73 35 NA 53 18
Study I, from [24]; Study II, from [23]; Study III, from [25]
relief for 12-24 hours without evidence of significant sedation, respiratory depres-
sion, or impairment of neuromuscular function. This report was soon followed by
other clinical studies noting remarkable analgesic efficacy and prompting the state-
ment that "never in the history ofmedicine has a concept progressed as rapidly from
laboratory experimentation to clinical application in man" [21]. Thousands of
literature citations [18-34] have since confirmed the remarkable efficacy ofepidural
opioids, and such techniques have gained considerable popularity in settings of
post-surgical, obstetrical, and chronic pain.
SpinalAnalgesia: Morphine
Morphine was first to receive FDA approval for epidural and intrathecal use and
remains the most widely investigated and extensively used spinal opioid. Morphine
has been employed to control post-operative pain following a variety of surgical
procedures, appears to improve post-operative respiratory function [18,27], and
encourages earlier ambulation [18,31,32]. While it has been found to be effective in
management of post-operative and cancer pain, morphine is less efficacious in
controlling labor pain, especially during second stage [18]. Epidural morphine is
usually administered at lumbar sites in doses ranging from 3 to 10 mg [22-24]. In
patients recovering from gynecological surgery, epidural morphine requirements
appeared to be inversely related to patient age, with 24-hour dose requirement in
milligrams equivalent to: 18 - age x (0.15) [22]. Thoracicsites ofadministration may
be employed for control of upper abdominal or thoracic pain [27]. Onset and
duration of epidural morphine analgesia following single-dose administration vary
according to the surgical stimulus, dose, and site of administration. Onset is usually
appreciated in 30-60 minutes, peak effect at 90-120 minutes, and duration of
analgesia ranges from 12 to 24 hours [24,25]. The superiority of epidural morphine
analgesia (as determined by descriptive and visual analogue scores) over pain relief
offered by parenteral opioids has been demonstrated following a wide variety of
post-surgical settings [18,23,25,31,32]. Epidurally administered morphine effectively
relieves visceral pain following abdominal or pelvic surgery [18,29,30,31] as well as
somatic pain associated with orthopedic procedures [25,26]. Three recent studies
noted that the quality and uniformity of post-operative analgesia provided by
epidural morphine was significantly better than that offered by IM morphine or
patient-controlled analgesia with morphine, while requiring only 1/A5 the parenteral
dose over the 24-hour study period [23-25] (Table 2).
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Following upper abdominal and major orthopedic surgery [26], epidural morphine
provided similar pain relief to that observed with 0.5 percent bupivacaine; however,
duration of analgesia was more prolonged, and there was a reduced incidence of
hypotension. A recent trend is to utilize continuous epidural morphine infusions and
combination infusions oflow-concentration bupivacaine and morphine for the more
severe pain associated with upper abdominal and thoracic surgery. El-Baz et al. [27]
evaluated the effectiveness of epidural bolus doses of morphine or bupivacaine and
continuous infusion of morphine for post-thoracotomy analgesia. They noted that
continuous infusion (0.5 mg/hour) provided excellent analgesia yet avoided the
systemic side effects observed with intermittent epidural dosing.
Improvements in post-surgical physiological parameters observed with epidural
morphine may be more important than reductions in pain scores. Using improve-
ments in respiratory effort as an index of pain relief, Bromage et al. [28] noted
significant benefit in patients receiving epidural morphine [FEVy = 67 percent of
baseline versus 45 percent noted with intravenous (IV) morphine]. Following gall
bladder surgery, epidural morphine provided a more uniform level ofanalgesia and
more effective respiratory effort than that noted with intramuscular opioids or
intercostal nerve block [29]. Rawal et al. [30] noted faster return of peak expiratory
flow and fewer pulmonary complications in grossly obese patients treated with
epidural morphine. Other investigators have demonstrated improved PaO2, reduced
incidence of pneumonia, earlier extubation, and decreased ileus in patients treated
with epidural morphine [26,30-32]. Two potentially important benefits, of reduced
post-surgical hospital stay [18,30,31] and improved post-operative course in high-risk
patients [32] with intrathecal and epidural morphine, remain to be confirmed in
large-scale, multi-centerevaluations.
Improved post-operative analgesia and pulmonary function have been reported
with intrathecally administered morphine in patients recovering from orthopedic
[18] and upper abdominal surgery [33]. Intrathecal morphine appears to be particu-
larly useful in gall bladder surgery, as doses of 0.2 mg provided up to 24 hours of
complete analgesia with minimal risk ofprecipitating sphincter of Oddi spasm [33].
With the development of 28- and 32-gauge catheters, the future role of continuous
intrathecal morphine analgesia looks especially promising. Continuous administra-
tion ofintrathecalmorphineoffers the advantage ofpotent, highlyselective analgesia
(100-fold reduction in morphine dose requirement over 24 hours) and improved
versatility in dosing.
Benefits of prolonged and selective analgesia noted with epidural morphine have
nevertheless been tempered by the considerable delay or latency noted in onset and
peak activity, inter-patientvariability in duration ofaction, and reports ofsignificant
adverse effects, including pruritus, nausea, vomiting, urinary retention, and, most
important, respiratory depression. Such morbidity has had a negative effect upon
patient and physician satisfaction, possibly delaying overall acceptance of the tech-
nique [18].
Adverse EventsAssociated with Morphine
Respiratory depression associated with epidurally administered morphine occurs
at two different intervals [18,19]. An early phase observed soon after administration
reflects rapid systemic absorption and is ofsimilar magnitude as that noted following
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TABLE 3
Epidural Infusions'
Bupivacaine Fentanyl Morphine Meperidine
0.05-0.1% 0.0005-0.001% 0.005-0.01% 0.1%
aConcentrations most commonly employed in post-surgical patients by the Yale University Acute Pain
Service
parenteral dosing. A later, more insidious depression occurring between 8-12 hours
after administration has been related to rostral flow ofCSF and delivery ofmorphine
molecules to the brain stem respiratory centers [18,28]. Risk factors underlying
delayed respiratory depression include high doses of morphine (over 5 mg, epidur-
ally), thoracic epidural administration, age over 60, patientswith pulmonary disease,
and perhaps greatest risk associated with concomitant administration of parenteral
opioids (Table 3).
Several large prospective evaluations have reported that mild depression of CO2
responsiveness is common following epidural administration of morphine (3-5 mg)
[18,34]. Even in the absence of the above-mentioned risk factors, the incidence of
clinically significant respiratory compromise has been found to range between 0.1
and 0.4 percent [34]. While delayed respiratory depression is usuallygradual in onset
and reversible with small doses of IV naloxone, it nevertheless requires frequent
respiratory checks and increased nursing supervision. The picture becomes further
complicated by the fact that respiratory rate is often a poor indicator ofventilatory
depression. Increasing somnolence may provide a more reliable warning of respira-
tory compromise [4] and should be evaluated frequently. Frequent level-of-
consciousness checks often interrupt normal sleep, however, and may lead to
increased patient anxiety and dissatisfaction.
A high incidence of nausea and vomiting [18,28] noted with epidurally adminis-
tered morphine is also believed related to rostral CSF flow with transport of
molecules to the chemoreceptor trigger zone (area postrema) in the brain stem.
Severe pruritus is another common and especially troublesome side effect that
further complicates therapy. Following epidural administration of morphine, the
incidence of pruritus requiring treatment may approach 70 percent in younger
individuals and in patients post-cesarean section, and is often of such severe
magnitude that it may compromise benefits of superior analgesia [23,24]. Pruritus
observed early after administration may be related to systemic histamine release and
responds to Hi antagonists; however, late pruritus involving the face and upper
trunk may be related to spinal reprocessing of afferent input whereby interrupted
nociceptive impulses are interpreted as itch [18,28]. Late pruritus does not respond
to antihistamine but is antagonized by small doses of naloxone [35] (refer to
treatment protocol below). A final serious side effect that adds to the morbidity of
epidurally administered morphine is urinary retention. This complication occurs
most often, but not exclusively, in young males and has been related to relaxation of
the bladder detrusor muscle [18]. Its occurrence is particularly disturbing to both
patient and surgeon, especially when frequent catheterization is required. Intrave-
nous naloxone and apomorphine may be effective antagonists in selected cases.
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TABLE 4
Factors Predisposing to the Development of Respiratory Depression Following Administration of
Epidural Opioidsa
Drug-Related Factors: Hydrophilic opioids
Large dose (mg)
Large volume (ml)
Repeated doses
Concomitant administration ofparenteral opioids
Patient-Related Factors: Age greater than 60 years
Debilitated individuals
Co-existing respiratory disease
Intrathecal administration
Raised intrathoracic pressure
Shock wave lithotripsy
Position
aSummarized from [18,28,41]
SpinalAnalgesia: Lipophilic Opioids
The morbidity associated with intrathecal and epidural morphine has reduced the
widespread application of "selective" spinal analgesia and has mandated investiga-
tion and utilization of other opioids having pharmacology better suited for this
application. Two classes of opioids have been considered as attractive alternatives
and include the lipophilicphenylpiperidines (fentanyl, sufentanil) and mixedagonist-
antagonists (butorphanol, buprenorphine).
The recognition that delayed respiratory depression (and other side effects) was
related to the retention and rostral spread of hydrophilic morphine molecules
[18,19,28. led investigators to turn their attention toward more lipid-soluble agents
that would theoretically leave the aqueous CSF and rapidly bind to lipid-rich spinal
tissue. A number of lipophilic opioids have been employed for control of acute
post-operative pain and chronic pain syndromes [36-54]. In general, these agents
provide a more rapid onset but shorter duration of analgesia than morphine
[36,37,40,49]. Unlike local anesthetics, the addition of epinephrine or dextran does
not significantly influence the quality or extend the duration ofanalgesia provided by
lipid-soluble opioids [18,40]. The lipophilic opioids are not associated with a high
incidence of pruritus or delayed respiratory depression. On the other hand, "early-
onset" respiratory depression, usually occurringwithin 30 minutes ofadministration,
has been observed [37,46,52].
Early-onset respiratory depression is believed to result from significant vascular
uptake (at epidural or subarachnoid venous plexi) of lipophilic agents and rapid
delivery via the systemic circulation to brain stem respiratory centers [18,19].
Early-onset depression, while measurable, is usually of lesser significance than
delayed respiratory compromise observed with morphine and is more likely to occur
in high-visibility, controlled settings (operating room, recovery room, intensive care
unit) with the anesthesiologist present or immediately available.
Commonly utilized lipophilic agents include the phenylpiperidine derivatives
meperidine, fentanyl, and, most recently, sufentanil. The physiochemical properties
ofmeperidine, including its moderately high lipid solubility, mu receptor specificity,
and local anesthetic properties, suggested a useful agent for analgesia in this setting.
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In an initial evaluation, Glynn et al. [36] reported that the onset of post-surgical
analgesia following epidural administration (100 mg) was extremely rapid. Benefits
were noted at five minutes, peaked at 30 minutes, and lasted eight hours. Analgesic
onset paralleled an equally rapid rise in CSF meperidine levels. In this regard, peak
levels noted between 15 and 45 minutes occurred significantly sooner than the
60-120-minute latency in the CSF peak reported with morphine. These investigators
noted few side effects and no evidence of delayed respiratory depression, findings
that have since been confirmed in larger controlled trials. Early-onset respiratory
depression has been reported following epidural administration of meperidine,
usually with doses exceeding 75 mg [18,36].
Fentanyl has surpassed meperidine as the lipophilic opioid of choice for epidural
analgesia. While not FDA-approved for administration into the epidural space, its
highanalgesicefficacy andsuperiorsafetyprofile have withstood the test oftime, and
it is commonly employed for control ofpost-operative and obstetrical pain [37-40].
Early animal studies indicated that epidurally administered fentanyl had an ex-
tremelyrapid onset, wasequally effective as morphine in blocking responses to pain,
and had no neurotoxic effects [15,17]. These properties, together with the fact that
fentanyl is marketed in a preservative-free solution, led investigators to evaluate its
usefulness in avariety ofsettings. Naulty and associates [37] reported that epidurally
administered fentanyl (50-100,ug) provided excellent post-cesarean section analge-
sia of rapid onset and three to four hours' duration. In patients recovering from
thoracotomy [38,39], epidural fentanyl provided rapid and effective analgesia and
improved both respiratory volume and flow rate. Fentanyl's reliability, rapid onset,
and short duration made itideally suited for continuous epidural infusion techniques
where the level ofanalgesia can be carefully titrated to the level ofpain stimulus and
rapidly terminated ifproblems should occur [18,38-40].
Several clinical reports [37-40] support the impression that epidurally adminis-
tered fentanyl is a very safe form of therapy and that significant respiratory
depression is unusual. While mild depression of CO2 response curves can be
expected within minutes of a fentanyl bolus (50-100,ug) or following prolonged
continuous infusion therapy [41], only one case of life-threatening respiratory
depression has been reported. Wells and Davies [41] observed CNS depression and
bradypnea in an obese male following extra-corporeal shock-wave lithotripsy. It is
unclear whether shock waves associated with this procedure may have caused
cephalad spread of fentanyl. In the usual clinical setting, it is often difficult to
promoterostral spread offentanyl. Gourlay et al. [42] noted that fentanyl, in contrast
to morphine and meperidine, did not migrate to the C7-T1 interspace following
lumbar epidural administration. This lack of rostral spread presumably reflects
fentanyl's rapid clearance from epidural and spinal sites of deposition (across
capillary endothelium and into the systemic circulation) and helps explain its
"segmental" analgesic properties. Since the rate of dural penetration and der-
matomalspread oflipophilic agent appears to be directly related to the surface area
in contact with thedrug[43], fentanyl's effectiveness in blunting pain associated with
upper abdominal and thoracicsurgerymay be improved when administered in larger
volumes ofsolution [44].
Fentanyl is an extremely versatile epidural analgesic. For this purpose, it may be
combined with lower-than-normal doses ofepidural morphine to minimize delays in
analgesic onset and reduce morphine's dose-dependent side effects [18]. Epidural
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fentanyl has also been combined with subtherapeutic doses of bupivacaine [45] to
achieve "supra-additive" analgesia that may effectively blunt pain associated with
first and second stage of labor, while having minimal effect on sympathetic tone or
motorstrength. Modification ofthistechnique may be useful in patients requiring an
effective anesthetic block, yet who, because ofpulmonary or cardiac disease, cannot
tolerate intercostal muscle weakness or the extensive sympathectomy that follows
high dermatomal blockade with more concentrated solutions oflocal anesthetic[39].
Small amounts of intrathecal fentanyl appear to increase the efficacy of spinal
anesthesia while providing one to two hours of post-operative analgesia [46]. This
technique is also indicated for use in debilitated patients who cannot tolerate high
levels of dermatomal blockade or extensive spinal sympathectomy.
The high lipid solubility and potency of fentanyl's chemical cousin, sufentanil,
suggested optimal characteristics for use as an epidural analgesic. In theory, large
numbers of sufentanil molecules should easily penetrate the dura and bind to spinal
tissues (resulting inrapid onset), while its high affinity for mu receptors would result
in amoderatelyprolonged duration ofactivity [47]. These characteristics were noted
in preliminary animal studies [48] and evaluations in human volunteers [49] where
epidural administration of sufentanil resulted in segmental analgesia without evi-
dence ofsignificant rostral spread.
Sufentanil is currently in the final phase of evaluation prior to FDA approval for
use as an epidural analgesic. A review of the medical literature has identified 28
studies, involving 900 adults and 15 children, investigating the safety and efficacy of
epidural sufentanil as a post-operative analgesic [50]. Sufentanil administered as a
single bolus, repeat bolus, and continuous infusion appears well suited for relief of
post-surgicalpain,painfollowing cesareansection, and foruse as an analgesic during
labor anddelivery[51-60]. When one summarizes the results ofthe above studies, it
becomes obvious that sufentanil provides extremely rapid and effective analgesia
without evidence ofdelayed respiratorydepression; however, dose requirements are
surprisingly high, early-onset ventilatory depression can occur, and its duration of
action (while dose-dependent) appears to be no greater than that observed with
fentanyl.
In a well-designed double-blind study [51], the onset of post-operative analgesia
was more rapid withepidurally administered sufentanil (50,ug) than with morphine
(5 mg). With sufentanil, pain at rest was alleviated at five minutes, while pain
associated with movement was absent after ten minutes. This speed of onset was
three to five times faster than that noted in the morphine group. On the other hand,
the duration ofmorphine analgesia was twice as long as that observed with sufenta-
nil.
After cesarean section, patients who received epidural sufentanil doses of 30 to 60
,ug experienced effective analgesia that ranged between 3.9 and 5.6 hours' duration
[52] (Table5). The addition ofepinephrine did not significantly prolong the duration
ofanalgesia in this study; however, research by Naulty and co-workers [53] suggests
that epinephrine may increase the duration of small epidural doses (25 ,ug) of
sufentanil while having little effect on doses above 50,ig.
Epidural analgesia following abdominal surgery appears to be of relatively short
duration, despite administration of sizable doses of sufentanil. Graf et al. [54] noted
that doses between 25 and 70,ug resulted in extremely effective analgesia; however,
duration ofpain relief(in whichpatients were totally pain-free) ranged between 140
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TABLE 5
Onset and Duration ofAnalgesia with Epidural Morphine and Sufentanil
Morphine Sulfate Sufentanil Sufentanil Sufentanil
5 mg 30mcg 45 mcg 60mcg
Onset of50% pain relief (minutes) 52a 15 15 15
Onset of90% pain relief (minutes) goa 30 30 15
Duration of analgesia, first dose (hours) 26a 3.9 4.5 5.6
aSignificant difference
From [52]
and 224 minutes. These investigators caution against using higher bolus doses to
extend duration, as a serious respiratory arrest occurred within seconds of adminis-
tering 70 ,ug of sufentanil. Other "immediate" onset respiratory arrests have been
reported following administration oflargeboluses orrepeatboluses [55,56]. Immedi-
ate respiratory depression may be related to inadvertent puncture of epidural vein
with intravascular administration or maysimply reflectvascularuptake ofsufentanil.
In this regard, peak plasma levels ofsufentanil are achieved within two minutes and
approach 0.31 ng/ml [49]. For this reason, we take similar precautions administering
sufentanil as we would any local anesthetic; that is, a test dose of5 ,ug is followed by
slowly administered incremental doses. Rapid removal of sufentanil from epidural
and subarachnoid vessels is also responsible forthe surprisingly high dosage required
for epidural analgesia and reflects the decreased gain in specificity and potency
noted with opioids ofincreasing lipophilicity [48,57]. Ifone measures the subcutane-
ous-to-epidural analgesia potency ratio, one finds a linear relationship with lipid-to-
water partition coefficient (i.e., selective gains in spinal analgesic effectiveness are
reduced as the agent administered increases in lipid solubility) [48].
Perhaps the most effective method of administering sufentanil is via continuous
infusion. This method takes advantage of sufentanil's rapid onset yet short duration
and minimizes respiratory risks associated with large bolus doses. Cheng et al. [58]
reported that continuous lumbar infusions of 0.3 jig/kg/hour provided rapid and
sustained analgesia with minimal side effects in patients recovering from intra-
abdominal surgery. We have noted similar effectiveness with lower doses (0.1-0.2
jig/kg/hour) following administration via thoracic catheters or when larger volumes
of dilute solution are infused at lumbar sites [59]. Sufentanil's rapid onset of
analgesia may also be used to advantage when combined with morphine. We have
also observed that the epidural combination of sufentanil (30 jig) and morphine (3
mg) provides extremely rapid analgesic onset while significantly reducing 24-hour
parenteral opioid requirements in patients recovering from major gynecological
surgery [60].
In conclusion, lipophilic opioids offer excellent spinal/epidural analgesia without
many of the liabilities observed with morphine. Their favorable attributes include
improved titratability (i.e., rapid and predictable analgesic onset) and lack of
significant rostral spread. Liabilities include short duration and respiratory compro-
mise associated with large-bolus doses. Lipid-soluble opioids outlined in this review
and new agents, possibly alfentanil and lofentanil, will play an increasinglyimportant
role in controlling acute post-operative and labor pain [18]. As mentioned above,
their safest and most efficacious method of administration will be as a continuous
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TABLE 6
Epidural Opioid Pharmacology/Pharmacokinetics'
Molecular Lipidb Epidural Onset Duration
Opioid Weight Solubility Dose (minutes) (hours)
Morphine 285 1.4 3-5 mg 60-90 12-24
Dihydro 287 8 1-2 mg 20 8-12
Morphine
Diacetyl 369 17 1-3 mg 15 6
Morphine
Meperidine 247 39 50-75 mg 10 4-8
Methadone 309 116 50-75 mg 15 8-10
Buprenorphine 468 200 300-500 mcg 15 5-7
Alfentanil 452 126 200-300mcg 10 2
Fentanyl 528 813 50-100 mcg 10 2-3
Sufentanil 578 1,778 40-50 mcg 5 3-3.5
aFrom [18,59]
' Octanol: water partition coefficient
infusion, either alone or in combination with smaller doses of epidural morphine or
other adjunctive agents.
The mixed agonist-antagonist class of opioids have certain theoretical advantages
for spinal application, namely, the presence of spinal kappa receptors (mentioned
above), which modulate visceral nociception, and the so-called "ceiling effect" for
respiratory depression, which would limit reductions in respiratory drive even if
molecules spread rostrally to the brain stem. Butorphanol, which is formulated in a
preservative-free solution, has been shown to provide up to 12 hours of effective
analgesia in patients recovering from cesarean-section delivery [61]. Other than
sedation (which lasted four to six hours), 5 mg ofepidurally administered butorpha-
nol was not associated with significant respiratory depression, nausea/vomiting, or
pruritus. Table 6 outlines epidural opioid doses commonly employed at our institu-
tion.
AdverseEffectsAssociated with Spinal Opioids
Side effects associated with epidural and intrathecally administered opioids
[18,28,62] may be treated effectively and should not be allowed to persist, as patient
jeopardy and dissatisfaction will soon outweigh the benefits of selective analgesia.
Patients treated with morphine or continuous opioid infusions should have respira-
tory rates monitored (every hour) by nursing staff and apnea-monitoring devices.
Increasing level of sedation is also monitored as a premonitory sign of impending
respiratory depression [4]. Patients in high-risk groups are best observed in an
intensive care unit setting, with naloxone at the bedside. Continuous oxygen satura-
tion and/or serial arterial blood gases should be followed in all high-risk patients.
Respiratory rate less than ten per minute or evidence of diminished tidal volume is
treated promptly with naloxone (40-80 p,g IV) followed by a naloxone infusion
(300-400 ,Lg/liter of crystalloid every eight hours). This dose will quickly reverse
respiratory depression yet will maintain spinal analgesia [35]. Table 7 outlines the
usefulness of naloxone infusion in patients treated with epidural morphine. Early-
onset generalized pruritus observed with morphine responds to diphenhydramine
(50-100 mg); however, late-onset truncal/facial itching may only respond to nalox-
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TABLE 7
Influence of Naloxone Infusion on Pain Relief and Adverse Effects ofEpidural Morphine (4 mg)
Naloxone Naloxone
Infusion Infusion Saline
10 mcg/kg-'/hour-' 5 mcg/kg-'/hour-' Infusion
Duration ofanalgesia (hour) 13.7a 17.8 18.5
Urinary retention (%) 33 53 67
Severe pruritus (%) 0 7 7
Nausea/vomiting (%) 7 13 20
Pulmonary complications (%) 7 7 20
aSignificant difference
From [35]
one administered as above. Similarly, the early occurrence of nausea is often well
controlled with compazine (10 mg) or droperidol (1.25 mg), while delayed nausea
[62] (4-12 hours past administration) associated with facial pruritus is best treated
with naloxone infusion or transdermal scopolamine patch. Urinary retention [18,62]
may respond to urocholine but may also require treatment with naloxone. Recent
evidence [18] suggests that small doses of nalbuphine (10 mg every four hours)
antagonize opioid side effects with less danger of reversing useful analgesia [35,63];
however, this mixed agonist/antagonist may increase the level of sedation. Side
effects appear to be infrequent and of lower magnitude in patients treated with
lipophilic opioids.
In summary, spinally administered opioids provide an excellent analgesic alterna-
tive to parenteral narcotics or epidural local anesthetics. This application is a new
one for an old family of drugs [21], yet these agents appear ideally suited to block
pain selectively as it first enters the CNS. Nevertheless, potential advantages of
spinal/epidural analgesia must be carefully balanced on a case-by-case basis against
the above-mentioned side effects and the greater invasiveness of the technique. We
have not considered the endogenous opioid peptides; however, the enkephalin
analogues (metkephamid, DADL), serotonin, alpha-2 agonists, and the family of
enkephalinase inhibitors mayoffer even more selective spinal analgesiawith minimal
systemic side effects [15,16,18]. These agents administered separately or in combina-
tion represent the future ofspinal/epidural pain suppression.
PATIENT-CONTROLLED ANALGESIA
Background
Patient-controlled analgesia (PCA) is a relatively new technique that permits
patients to treat pain by directly activating doses of intravenous opioids. The patient
is allowed to control the rate ofdrug administration (within prescribed limits), based
upon his or her appreciation ofthe degree ofpain, and thereby correct for individual
differences intolerance,variability inpharmacokinetics, orinappropriate "screening"
by house staff. PCAwith intermittent intravenous doses ofopioid analgesics was first
described by Sechzer in 1968 [64]. While its main use during its first decade of
application was experimental (i.e., the evaluation of equianalgesic dosing in drug
trials), PCA has since taken on a greater role in the analgesic management of
post-operative and labor pain.
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FIG. 3. "The analgesic
window": The theoretical
plasma concentrations which
provide optimal analgesic
benefit, while minimizing
adverse effects. From [7,65].
It is well recognized that, with appropriate titration of drug, marked variation in
opioid requirement may be evident among populations of patients recovering from
the same operative procedure; however, PCA allows individuals to maintain ade-
quate analgesia regardless ofchanges in pharmacokinetic parameters, or changes in
pain intensity over time. PCA systems work under a number ofassumptions [3,5,65],
the first assumption being that opioid side effects occur at higher brain concentra-
tions than those needed to produce analgesia [5,65]. While massive opioid doses
could theoretically eliminate all pain (but with unacceptable levels of respiratory
depression), an adequate level of analgesia usually represents a compromise be-
tween tolerable pain and troublesome side effects. A second assumption is that pain
intensity is rarely constant. Post-operative pain is intensified by movement and
coughing and seems to have a circadian rhythm, with increasing pain at night [4,6]. A
final assumption is that the entire spectrum of pain relief occurs within a narrow
range ofplasma analgesic concentration subject to individual variation [3,4,65,66].
Presently, several patient-controlled analgesia systems are sold in this country and
include devices manufactured by Abbott, Bard, and Pharmacia. These systems all
incorporate a microprocessor that allows the patient to interact with an infusion
pump connected to his or her established intravenous line. Patients usually activate
the pump by pressing a button connected to the apparatus. A pre-programmed
amount of opioid is then administered over 10-30 seconds. A lockout interval is
simultaneously begun after each injection, thereby preventing a second dose from
being delivered within a preset time interval (usually between 5-15 minutes, depend-
ing upon dose and agent selected). Potential overdosage is prevented by limiting the
amount of opioid delivered per bolus and limiting the number of injections over a
given time interval. In addition, increasing patient sedation usually decreases pump
activation enough to prevent overdosage.
Several delivery options are available with second-generation PCA systems. The
most popular and simple is the bolus dose-on-demand system. This system simply
responds to the patient's activation with a pre-programmed dose and lockout
interval. A more sophisticated delivery system incorporates a minimal (basal)
constant-rate infusion plus patient-activated bolus doses on demand. This system
may be best utilized with rapid-acting, short-duration agents.
By utilizing smaller boluses and more frequent dose intervals than IM PRN
dosing, PCA more closely approximates a continuous infusion (Fig. 3). Like continu-
ous infusions (which could be described as having infinitely small doses and inter-
-1
c
a)
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vals), PCAhasthe advantage ofminimizing fluctuations inplasma drugconcentration.
Unlike continuous infusions, PCA plasma levels do not depend to as great a degree
on drug elimination remaining constant [3,4]. Since PCA is precisely titrated by the
patient, very stable steady-state plasma levels and optimal analgesic concentration
are maintained. This condition is important since, in the case ofopioids, analgesia is
associated with a narrow range of plasma concentration, above which there is no
increase in pain relief and side effects begin to dominate. In this respect, the
minimum effective plasma concentration (MEC) ofmorphine has been calculated to
be 20 ng/ml or 2 mg/hour in a 70 kg patient [65,66]. It should be appreciated that
MEC is a dynamic definition, influenced by patient tolerance and level of pain
intensity. An MEC of 80-90 ng/ml is safely tolerated, and plasma morphine
concentrations are severalfold higher than this amount following IM administration.
As a rule, patients over 60 years ofage require one-third to one-halfless PCAopioid
than healthy adults aged 20 to 40 years [6].
Finally, when administering opioid analgesics, the optimal plasma concentration
must be rapidly achieved, and the natural accumulation time offour half-times must
be bypassed with the administration of a "loading" dose. The loading dose is a
relatively large bolus of drug (10-15 mg morphine), preferably administered in
divided IV doses, which enables plasma concentrations to reach a level where
maintenance PCA doses can maintain a steady state [3,4,65,66].
Objectives ofPCA
The objectives ofPCAhave been described as: (1) to achieve effective analgesia as
rapidly as possible with the minimum dose of opioid; and (2) to maintain continu-
ously effective analgesia for extended periods, during which the patient should be
able to maintain a normal sleep pattern [3,64,65]. As listed below, PCAoffers several
practical and theoretical advantages over traditional dosing regimes.
1. Superior pain reliefwith less medication
2. Less sedation during daytime hours
3. Decreased delaybetween request for analgesic and relief
4. Improved respiratory function
5. Minimized inappropriate screening
6. Accommodation for diurnal changes
7. Accommodation for inter-individual analgesic requirements
8. Ability to titrate analgesic in response to need (i.e., movement)
While there have been fewwell-controlled studiescomparing PCAwith traditional
IM PRN dosing, the impression from investigators utilizing this modality is that it
offers not only superior pain relief, but also reduces total opioid requirements and
need for associated medications [23,24]. Patients inevitably find themselves titrating
pain against sedation or other opioid side effects. They are usually willing to accept
some amount ofpain in order to have a clear sensorium. At the same time, they are
comforted with the fact that, if they choose to, they can suppress an even greater
amount of their pain [3,23,24]. By administering small amounts of opioid intrave-
nously without being dependent upon the house staff, the series of events described
in Fig. 1 is eliminated, and the interval between a request for analgesia and relief is
markedly reduced.
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A superior level of analgesia may contribute toward an improved post-operative
course, especially in higher-risk patients. Improved post-operative forced vital
capacity and an overall decrease in pulmonary complications have been reported in
patients utilizing PCA with morphine following thoracic and upper abdominal
surgery [3,6]. Obese patients utilizing PCA following gastric bypass surgery had
improved post-operative pulmonary function and required significantly less total
medication than weight-matched controls [5,6]. Although mild respiratory depres-
sion is commonly reported with PCA (or any form of opioid analgesic therapy, for
that matter), only two cases of severe depression have been reported. In both
instances, drug overdose was secondary to house staff-nursing error rather than
patient misuse or pump malfunction [67].
VariablesInfluencingPCA
The amount of medication (mg) administered during each PCA bolus dose is
important and must be adjusted in relation to patient age, weight, site, and extent of
surgery (i.e., there is no "cookbook" dose; each patient must be assessed individu-
ally). If the size of the bolus dose is too small, patients will tend to fail PCA, as they
often experience incomplete analgesia. If, on the other hand, the dose is too high,
patients tend to fail PCA as they experience a high incidence ofside effects (nausea,
sedation, dysphoria) [68]. When patients associate the appearance of side effects
shortly after pressing the PCA button, they tend to reduce self-administration and
begin to experience very high pain scores. On our PCAservice, nausea and vomiting
appear to be the most common (45 percent in gynecological surgical patients, 15
percent in orthopedic surgical patients) and troublesome side effects. In a recent
study, we noted that application of transdermal scopolamine (Transderm Scop®)
significantlyreduced the incidence and severityofnausea inpatients recoveringfrom
major gynecological surgery [69]. We also observed that the addition ofPhenergan®
(hydroxyzine) to PCA morphine (12.5 mg PhenerganS added to every 30 mg
morphine) reduced the severity of nausea and vomiting, while not increasing the
level ofsedation followinggynecological surgery [70].
While PCA and epidural administration of opioids appear to provide a superior
level of analgesia [3,23-25], it was necessary to compare these new methods with
traditional IM dosing in patients recovering from the same surgical procedure. In a
controlled randomized study reported by Harrison et al. [23], 60 patients recovering
from cesarean-section delivery were treated with either epidural morphine (5 mg),
PCA morphine (2 mg/eight-minute lockout), or IM morphine (10-15 mg/three
hours). In contrast to previously mentioned PCA studies [3,5,7], we were unable to
demonstrate significant differences in quality of analgesia or total opioid require-
ment when patients treatedwith PCAwere comparedwith the IM group. Patients in
the epidural group, while benefiting from a significantly improved level of analgesia
duringthe first 16post-operative hours, were troubledby a high incidence ofpruritus
(70 percent, 40 percent requiring treatment). Thus, despite higher pain scores than
those observed in the epidural group, patient satisfaction with the level of relief
provided by PCA was comparable. Factors responsible for the lack of correlation
betweenpain scores and highpatient satisfaction in the PCAgroup maybe related to
the uniform level of analgesia, lack of troublesome side effects, and an awareness
that reliable analgesia wasonly a button press away [23].
368CONTROL OF POST-OPERATIVE PAIN
Despite the high patient satisfaction noted above, it appeared that patients were
more pleased with the independence and control PCA afforded than with the
analgesic agent administered. While morphine remains the PCA drug of choice in
the United States, it is probably not the ideal opioid analgesic to be used in this
setting [71,72]. An agent having faster onset, less sedation, and fewer adverse effects
might further increase patient satisfaction and increase analgesia to levels compara-
ble to that seen with epidural morphine. Oxymorphone, hydromorphone, and
meperidine are semisynthetic opioid agonists that have many attributes considered
useful in the setting ofPCA, including high analgesic efficacy, rapid onset ofeffect, a
lower level ofsedation, and minimal histamine release at clinically useful doses. Two
recent studies [71,72] have documented the effectiveness of oxymorphone and
meperidine for use in PCA. Oxymorphone provided effective analgesia when admin-
istered by patients recovering from cesarean delivery [71]. In this prospective
evaluation, self-administered incremental doses (4 jig/kg every eight minutes) were
given as required over the next 24 hours. During this interval, mean oxymorphone
dose requirements were 16 mg per patient or 1/6 the average morphine dose required
in this patient population. Although the majority ofpatients reported mild pain, even
those occasionally reporting moderate pain (viseolinear pain scores of4-6 on a scale
of 10 = worst pain) expressed complete satisfaction with their level of analgesia and
lack of side effects.
In a follow-up double-blinded randomized evaluation [72], patients recovering
from cesarean delivery received an analgesic base of either morphine (6 mg),
meperidine (60 mg), or oxymorphone (1 mg), and were then allowed to self-
administer incremental opioid doses as required over the next 24 hours. Incremental
doses were morphine (1.8 mg), meperidine (18 mg), or oxymorphone (0.3 mg) with a
lockout interval ofeight minutes between administrations. While all three treatment
groups reported excellent analgesia, those receiving oxymorphone and meperidine
tended to report lower pain scores at rest, less sedation, and higher patient
satisfaction than patients treated with morphine. Analgesia appeared to be more
rapid in onset and more uniform in patients self-administering oxymorphone. An
important finding was that the oxymorphone group had significantly less pain with
movement. This useful quality suggested superior drug efficacy in patients who were
attempting to ambulate or to hold and nurse their newborns. Also important was the
fact that patients treated with meperidine had minimal sedation and the lowest
incidence of side effects. In summary, both oxymorphone and meperidine in doses
listed above maybe more preferable PCA agents thanmorphine in the post-cesarean-
section delivery patient. These findings will be re-examined in patients recovering
from general surgery or suffering from the pain associated with malignancy.
One disadvantage of meperidine in the obstetrical setting is the fact that its
metabolite, normeperidine, tends to concentrate in breast milk. In a recent evalua-
tion ofnursing mothers [73], we noted slightly depressed neonatal Brazelton scores
in infants whose mothers were utilizing PCA meperidine for post-cesarean delivery
analgesia. In contrast, scores in infants exposed to morphine (PCA) were normal.
Normeperidine levels in breast milk remained elevated during a five-day sampling
period, while concentrations of morphine and its major metabolite, morphine-6-
glucuronide, were low. For this reason, we avoid meperidine in parturients attempt-
ing to breast feed following cesarean delivery.
In a final study [74], oxymorphone and morphine were administered in a continu-
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ous (basal) infusion plus superimposed PCA infusion mode in patients recovering
from cesarean delivery. Using a second-generation PCA pump (Abbott Lifecare II)
capable ofproviding this dual form ofnarcotic administration, we noted significantly
improved pain scores associated with movement and ambulation. Unfortunately, the
incidence of side effects (nausea/vomiting) was increased. We are about to repeat
this study with the addition of Transderm Scop® or placebo patches to determine
whether we can maintain this excellent level of pain reliefwhile minimizing nausea
andvomiting.
Work directed at improving PCA therapy continues, and investigators are begin-
ning to document earlier patient ambulation, decreased overall morbidity (reduced
thrombophlebitis and pneumonia, improved wound healing, reduced opioids and
adjunctive medication requirement), and possibly earlier hospital discharge [3,75].
These findings are of critical importance to hospital administrators and third-party
insurance carriers, as they evaluate the overall cost-effectiveness of newer analgesic
techniques.
INTERPLEURAL CATHETERS
Since the description of interpleural analgesia by Reiestad and Stromskag [76], a
number of investigators have modified and improved the safety and efficacy of the
technique for management of post-operative pain following cholecystectomy, tho-
racic surgery, and breast reconstruction surgery [76-78]. Kambam et al. [77] demon-
strated the efficacy of the technique in managing post-operative pain in patients
recovering from lateral and posterior thoracotomies.
Interpleural injection of local anesthetic is able to block indirectly intercostal
nerves, splanchnic nerves, and blunt directly irritation ofthe parietal pleura [76-78].
In our experience, the technique effectively blunts both visceral and abdominal wall
pain but may have to be supplemented with low doses of parenteral opioid or
anxiolytic agents in order to achieve best results. Interpleural catheter placement is
frequently associated with clinically insignificant side effects such as small he-
matoma, non-leaking lung puncture, or small pneumothoraces. The risk for serious
complications such as tension pneumothorax is low but exists irrespective of tech-
nique, needle, or syringe used [79].
A 19-gauge open-tip epidural catheter is inserted at the anterior axillary line via a
17-gauge Touhy epidural needle [76-79]. A distinct click is noted following penetra-
tion of the parietal pleura and is associated with a loss of resistance noted in a
saline-filled syringe. The catheter is carefully inserted 3-5 cm (toward the shoulder)
and taped in place; 2 ml increments ofbupivacaine 0.5 percent are injected every two
to three minutes until a total of 15-20 ml has been administered. Pain reliefis noted
within five to ten minutes following administration. At this time, the epidural
catheter may be connected to an infusion pump set to deliver bupivacaine 0.25
percent at a rate of8-10ml/hour-' [80,81].
A number of studies [78,80,81] indicate that the technique provides maximum
analgesic benefit when local anesthetic is continuously infused, rather than by
intermittent boluses administered in response to patient complaint of pain. The
interval between intermittent dosesvaries but can be as frequent as every four hours
(this rate obviously becomes very labor-intensive and is associated with risk of high
plasma bupivacaine concentrations immediately following re-bolus). Laurito et al.
[81] recently compared the efficacy and safety of continuous infusion versus bolus
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injections in providing post-operative analgesia following cholecystectomy and noted
a more uniform level of pain relief and reduction in PCA (morphine) requirements
in the continuous infusion group. Continuous interpleural analgesic technique has
also provided effective analgesia in pediatric patients recovering from thoracotomy
[82].
Patients receiving interpleural analgesia often benefit from superior intra-
operative and post-operative cardiovascular stability. While such stability was ini-
tially attributed to superior analgesia, recent studies [77-79] suggest direct blockade
ofthe sympathetic chain and splanchnic outflow, causing a sympathetic denervation.
Such modification of endocrine and stress responses needs to be studied in greater
detail.
Finally, interpleural analgesia may provide effective therapy in non-surgical
patients suffering from upper abdominal visceral pain. Durrani et al. [83] recently
noted that long-lasting relief of upper abdominal pain secondary to pancreatic
cancer was achieved by injections of8 ml 0.5 percent bupivacaine. They suggest that
the technique may also be useful in patients suffering from pancreatitis.
CONCLUSION
The preceding pages have commented on deficiencies associated with traditional
analgesic regimens, described new and highly effective methods of controlling pain,
and provided rationale for their use in the post-surgical period. Spinally adminis-
tered opioids provide the most significant gain in analgesic potency (as compared
with traditional IM dosing); however, the technique is labor-intensive and associated
with a higher risk of adverse events. Nevertheless, the higher intensity ofpain relief
noted with continuous epidural opioid infusions is capable of providing "pain
prevention" or lack of pain perception. Pain prevention is an important goal in
high-risk and debilitated individuals, as it is associated with greater cardiovascular
stability and improved pulmonary function in the immediate post-surgical period
[32].
Although the intensity ofpain relief provided by PCA is of lower magnitude than
that observed with spinal opioids, the incidence of adverse effects is also lower;
moreover, the uniformityofreliefand patient satisfaction with therapy is superior to
that provided by traditional therapy.
Optimal delivery ofspinal opioids, PCA, and interpleural analgesic therapy is best
provided by a dedicated Acute Pain Service. The role of the service includes: (1)
24-hour availability oftrained personnel who can assess and treat adverse events; (2)
availability of personnel who could, if necessary, modify analgesic therapy, thereby
maximizing overall effectiveness; (3) provision of quality assurance and continual
improvement in therapy. Pain services in academic settings are also obliged to
provide education and trainingoffuture clinicians skilled in pain management and to
initiate research protocols. Such investigations have not only optimized analgesic
delivery but have developed effective treatment protocols to reduce adverse effects.
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